Veterinary and Comparative Oncology is a leading academic journal published by WILEY, providing a vital platform for the dissemination of groundbreaking research in the field of veterinary oncology. With an impressive impact factor and ranked as Q1 in the Veterinary (Miscellaneous) category for 2023, the journal is recognized for its quality and influence, placing it in the top 10% of its field. Covering a wide array of topics, from the pathogenesis of tumors in animals to innovative treatment strategies, it aims to enhance the understanding of cancer biology and therapy in veterinary medicine. The journal has an E-ISSN of 1476-5829, with its scope expanding from 2007 to 2024, reflecting an ongoing commitment to the advancement of veterinary science. Located in the United Kingdom, its global reach facilitates the exchange of knowledge among researchers, professionals, and students. For those interested in significant and impactful studies, Veterinary and Comparative Oncology remains an essential resource in the ever-evolving landscape of veterinary medicine.

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.

Diagnostic Pathology is a prominent open-access journal published by BMC, dedicated to advancing the field of pathology by providing a platform for high-quality research findings since its inception in 2006. Based in the United Kingdom, the journal covers a broad spectrum of topics within the realms of histology, pathology, and forensic medicine, facilitating discussions that are crucial for both clinical and laboratory settings. With an impressive impact factor that places it in the Q2 category across multiple categories including Histology and Miscellaneous Medicine, it ranks favorably in Scopus with notable positions in the 71st and 55th percentiles for Pathology and Histology respectively. As a valuable resource for researchers, professionals, and students alike, Diagnostic Pathology promotes the dissemination of cutting-edge studies and findings, thereby contributing significantly to the evolving landscape of medical science. The journal’s commitment to open access enhances its accessibility, ensuring that valuable research is freely available to a global audience.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, published by Lippincott Williams & Wilkins, is a premier academic journal dedicated to the intricate field of gynecological pathology, serving a critical role in advancing the understanding of diseases related to women's reproductive health. Since its inception in 1982, this journal has established itself as a key resource for researchers, clinicians, and students, with a current impact factor that reflects its esteemed reputation; it is ranked in the Q2 category for both Obstetrics and Gynecology, as well as Pathology and Forensic Medicine, signifying its prominence in academic circles. The journal's scope encompasses a wide array of topics, including histopathological findings, diagnostic methodologies, and evolving therapeutic strategies, all pivotal to enhancing patient care. With a steadfast commitment to disseminating high-quality research until the projected year of 2024, the INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY is an essential read for those looking to stay abreast of the latest developments in this vital area of medical science.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

The American Journal of Surgical Pathology, published by Lippincott Williams & Wilkins, is a premier peer-reviewed journal serving as a vital resource for pathologists, surgeons, and researchers in the medical field. With an impressive impact factor reflective of its esteemed standing in the academic community, the journal ranks in the Q1 quartile for Anatomy, Pathology and Forensic Medicine, and Surgery as of 2023. The journal's Scopus rankings further highlight its significance, placing it within the top tiers in multiple medical disciplines. Established in 1977 and continuing through 2024, its scope encompasses groundbreaking research, critical reviews, and updates in surgical pathology, making it an essential tool for advancing the scientific community's understanding of disease mechanisms and therapeutic approaches. Researchers, clinicians, and students will find both comprehensive studies and innovative insights, ensuring they remain informed about the latest developments in surgical pathology.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.